Market Overview

UPDATE: Morgan Stanley Reiterates On Biogen Idec As Positive RPC1063 Data Poses Threat To Tecfidera

Related BIIB
AC Immune Is An Alzheimer's Pure Play With A Lot On The Line
John Stumpf And 15 Major CEO Departures In 2016
Best Near-Term Price Gains Ahead For: Established Biotechnology Stocks (Seeking Alpha)

In a report published Tuesday, Morgan Stanley analyst Matthew Harrison reiterated an Overweight rating on Biogen Idec (NASDAQ: BIIB), but removed the $395.00 price target.

In the report, Morgan Stanley noted, “RPC1063 is an oral S1P1 receptor modulator (same as Novartis' Gilenya) which could compete with Biogen's Tecfidera. Receptos mgt. reported an 86% decline in cumulative gadolinium-enhancing lesions compared to pbo. On safety, first dose heart rate reductions were <2 bpm (mean max) and no pt dropped below 45 bpm (first dose cardiac effects are a key issue with Gilenya) and the hepatic profile was described as favorable as compared to Gilenya (we expect details at ECTRIMS in the fall). Receptos' PhIII trial (RPC1063 vs Avonex, 1,200 RRMS pts) is ongoing with reduction in annualized rate of relapse (ARR) at 24 months as the primary endpoint.”

Biogen Idec closed on Monday at $318.16.

Latest Ratings for BIIB

Oct 2016JefferiesMaintainsHold
Sep 2016JefferiesDowngradesBuyHold
Aug 2016Morgan StanleyMaintainsOverweight

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

Posted-In: Matthew Harrison Morgan StanleyAnalyst Color Price Target Analyst Ratings


Related Articles (BIIB)

View Comments and Join the Discussion!